CAS 1541762-55-3

Cyslt1 antagonist Q8

CAS : 1541762-55-3

Cyslt1 is a receptor tyrosine kinase that has been implicated in the development of colorectal cancer. Cyslt1 antagonist Q8 is an antibody that binds to the extracellular domain of cyslt1 and prevents it from binding to epidermal growth factor (EGF), which blocks its signaling. The inhibition of EGF signaling by Cyslt1 antagonist Q8 leads to diminished cancer cell proliferation and colony formation, decreased tumor size, and increased apoptosis. Cyslt1 antagonist Q8 also inhibits the production of TNF-α and VEGF in colon cancer cells, leading to decreased metastasis. This drug may be useful for the treatment of metastatic colorectal cancer.

Formule : C₁₇H₁₄ClNO₂

Degré de pureté : Min. 95%

Masse moléculaire : 299.7 g/mol

Ref: 3D-RLC76255

Q8 hydrochloride

CAS : 1541762-55-3

Q8 is an antagonist of cysteinyl leukotreine receptor. Q8 inhibits VEGF-independent angiogenesis.

Formule : C₁₇H₁₄ClNO₂

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 299.75

Ref: TM-T28481